INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, cilt.20, sa.12, ss.2118-2121, 2017 (SCI-Expanded)
AimColchicine prophylaxis is the single most important factor in ameliorating familial Mediterranean fever (FMF) for the prevention of both attacks and secondary amyloidosis. The aim of the present study was to evaluate the exact proportion of those patients who do not respond to colchicine and to characterize their demographic, sociodemographic and clinical aspects.